Core Viewpoint - The A-share market is expected to experience structural differentiation and overall pressure in Q3 performance due to weak demand recovery, with the sustainable aviation fuel (SAF) industry chain showing significant growth, highlighted by the performance of companies like Langkun Technology [1] Group 1: Financial Performance - Langkun Technology reported a revenue of 1.386 billion yuan for the first three quarters of 2025, a year-on-year increase of 0.17%, and a net profit attributable to shareholders of 249 million yuan, up 28.89% [1] - In Q3 alone, the company achieved a revenue of 532 million yuan, representing an 8.31% year-on-year growth, with a net profit of 102 million yuan, up 39.55% [1] - The main driver for the growth in Q3 was the enhanced profitability of the biomass resource regeneration business [1] Group 2: Competitive Advantages - Langkun Technology possesses strong supply chain competitive advantages by securing government contracts for kitchen waste disposal, leading to lower production costs for oils and higher profit margins for processed products [2] - The company holds the largest market share in first-tier cities for kitchen waste disposal BOT projects, with five large-scale projects capable of processing over 1,000 tons per day [2] - A collaboration with the Beijing Tongzhou Urban Management Committee to build a biomass resource regeneration center reflects the company's strong technical capabilities and market recognition [2] Group 3: New Business Developments - The synthetic biology manufacturing business, particularly the development of human milk oligosaccharides (HMOs), has shown significant progress and is expected to become a new growth engine for the company [2] - The market for HMOs in China is projected to reach approximately 675.8 billion yuan, with potential for further growth driven by increasing health awareness and consumption [2] Group 4: Corporate Actions and Market Position - Langkun Technology established a wholly-owned subsidiary, Langjian Bio, to focus on the R&D, production, and sales of HMOs, with its lactose-N-neotetraose (LNnT) product recently approved by the National Health Commission [3] - The company has distributed a total cash dividend of 121 million yuan since its listing, with a cumulative payout ratio of 57% [3] - Actions such as share buybacks, increasing performance targets for stock incentives, and shareholding increases by the controlling shareholder demonstrate confidence in future growth [3][4]
朗坤科技：业绩新高+分红稳健，估值性价比凸显